Cardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by University of Sao Paulo.
Recruitment status was  Active, not recruiting
Cristália Produtos Químicos Farmacêuticos Ltda.
Information provided by:
University of Sao Paulo Identifier:
First received: August 29, 2007
Last updated: February 18, 2009
Last verified: February 2009
The purpose of this study is to determine if bupivacaine (75% levobupivacaine plus 25% racemic bupivacaine) with vasoconstrictor is effective and safety as ropivacaine in brachial plexus block for orthopedic surgery.

Condition Intervention Phase
Injuries, Hand
Anesthesia Conduction
Anesthetics, Local
Drug: Bupivacaine
Drug: Ropivacaine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)

Resource links provided by NLM:

Further study details as provided by University of Sao Paulo:

Primary Outcome Measures:
  • Cardiovascular safety [ Time Frame: Two days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Anesthesia Analgesia quality [ Time Frame: Two days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 48
Study Start Date: October 2007
Estimated Study Completion Date: July 2009
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: B
Arm number B corresponds to the Bupivacaine group.
Drug: Bupivacaine
Dosage: 150mg at once for anesthesia induction
Active Comparator: R
Arm number R corresponds to the Ropivacaine group.
Drug: Ropivacaine
Single dose of ropivacaine, 150mg

Detailed Description:

The intoxication by Bupivacaine is considered life threatening. Currently the most safety local anesthetic in substitution to bupivacaine is ropivacaine, however in Brasil there is a bupivacaine mixture of 75% levobupivacaine plus 25% racemic bupivacaine. The research design is:

Patients involved: 48; age: 18 to 40 years old; both sex; ASA I and II. Surgery: elective upper extremity orthopedic surgery. Anesthesia technique: brachial plexus block. Primary endpoint: cardiovascular safety; analysis by continuous Holter. Secondary endpoint: anesthetic and analgesic efficacy.


Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients involved: 48; ASA I and II;
  • Surgery: elective upper extremity orthopedic surgery.

Exclusion Criteria:

  • Contraindications to anesthesia technique and/or to local anesthetic;
  • Participation in different trials in the last two months;
  • Antiretroviral users;
  • Obesity.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00523289

Sponsors and Collaborators
University of Sao Paulo
Cristália Produtos Químicos Farmacêuticos Ltda.
Study Chair: José Otávio C Auler Junior, PhD/Chairman Hospital das Clínicas - Medicine School of the University of São Paulo
  More Information

Responsible Party: José O.Costa Auler Jr - Full prof.Anesthesiology USP, University Sao Paulo Identifier: NCT00523289     History of Changes
Other Study ID Numbers: CRT029 
Study First Received: August 29, 2007
Last Updated: February 18, 2009
Health Authority: Brazil: National Health Surveillance Agency

Keywords provided by University of Sao Paulo:
Upper Extremity
Local anesthetic

Additional relevant MeSH terms:
Anesthetics, Local
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on April 27, 2016